
5822-00322 — Canadian Institutes of Health Research
The complainant alleged that the Canadian Institutes of Health Research (CIHR) improperly withheld information under subsections 18(a), 19(1), and 20(1)(b) of the Access to Information Act, concerning an individual's role on the Pfizer Lyme Disease Advisory Board and their research project. During the investigation, the complainant narrowed the scope to three specific sections of records withheld under paragraph 20(1)(b). The OIC sought representations from the third party (Nominated Principal Investigator via Queen's University), who had no concerns with disclosure. CIHR subsequently conceded that the threshold for paragraph 20(1)(b) had not been met and indicated preparedness to release the information. The Commissioner found that the information at issue, describing aspects of a proposed research network, was not financial, commercial, scientific, or technical as required by paragraph 20(1)(b). Therefore, the Commissioner concluded that the exemption did not apply. The complaint was found to be well founded, and CIHR was ordered to disclose the information.
Ontario
British Columbia
Alberta
Saskatchewan
Manitoba
Quebec
Nova Scotia
New Brunswick
Prince Edward Island
Newfoundland and Labrador
Yukon
Northwest Territories
Nunavut